Supplementation with branched-chain amino acids attenuates hepatic apoptosis in rats with chronic liver disease

Nutrition Research

Volumn 32, Issue 7, 2012, Pages 522-529

  Kuwahata, Masashi ^a   Kubota, Hiroyo ^a   Kanouchi, Hiroaki ^b   Ito, Shunsuke ^a   Ogawa, Aki ^a   Kobayashi, Yukiko ^a   Kido, Yasuhiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Branched chain amino acids; Carbon tetrachloride; Fibrosis; Liver diseases; Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; BRANCHED CHAIN AMINO ACID; CARBON TETRACHLORIDE; CASEIN; CELLULOSE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOCHROME C; ISOLEUCINE; LEUCINE; MESSENGER RNA; MINERAL; PROTEIN BAX; RAPESEED OIL; SOYBEAN OIL; STARCH; SUCROSE; VALINE; VITAMIN MIXTURE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; ENZYME ACTIVITY; FOOD INTAKE; LIVER CYTOSOL; LIVER FIBROSIS; LIVER LEVEL; LIVER MITOCHONDRION; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT;

AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARBON TETRACHLORIDE; CASEINS; CHRONIC DISEASE; DIETARY SUPPLEMENTS; IN SITU NICK-END LABELING; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEQUENCE ANALYSIS, RNA;

RATTUS;

EID: 84865187080     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.06.007     Document Type: Article

References (41)

1. Inoue S., Browne G., Melino G., Cohen G.M. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ 2009, 16:1053-1061.
2. Malhi H., Guicciardi M.E., Gores G.J. Hepatocyte death: a clear and present danger. Physiol Rev 2010, 90:1165-1194.
3. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86:147-157.
4. Jurgensmeier J.M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J.C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998, 95:4997-5002.
5. Takehara T., Tatsumi T., Suzuki T., Rucker E.B., Hennighausen L., Jinushi M., et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004, 127:1189-1197.
6. Guicciardi M.E., Gores G.J. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis 2010, 30:402-410.
7. Bantel H., Lugering A., Poremba C., Lugering N., Held J., Domschke W., et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001, 34:758-767.
8. Natori S., Rust C., Stadheim L.M., Srinivasan A., Burgart L.J., Gores G.J. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001, 34:248-253.
9. Fox C.K., Furtwaengler A., Nepomuceno R.R., Martinez O.M., Krams S.M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001, 21:272-279.
10. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
11. Pockros P.J., Schiff E.R., Shiffman M.L., McHutchison J.G., Gish R.G., Afdhal N.H., et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007, 46:324-329.
12. Shiffman M.L., Pockros P., McHutchison J.G., Schiff E.R., Morris M., Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor-a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010, 31:969-978.
13. Rosen H.M., Yoshimura N., Hodgman J.M., Fischer J.E. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 1977, 72:483-487.
14. Michitaka K., Hiraoka A., Kume M., Uehara T., Hidaka S., Ninomiya T., et al. Amino acid imbalance in patients with chronic liver diseases. Hepatol Res 2010, 40:393-398.
15. Sato S., Watanabe A., Muto Y., Suzuki K., Kato A., Moriwaki H., et al. Clinical comparison of branched-chain amino acid (l-Leucine, l-Isoleucine, l-Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN study). Hepatol Res 2005, 31:232-240. LIV-EN Study Group.
16. Muto Y., Sato S., Watanabe A., Moriwaki H., Suzuki K., Kato A., et al. Effect of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-713.
17. Nakaya Y., Okita K., Suzuki K., Moriwaki H., Kato A., Miwa Y., et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007, 23:113-120.
18. Nishiguchi S., Habu D. Effect of oral supplementation with branched-chain amino acid granules in the early stage of cirrhosis. Hepatol Res 2004, 30S:S36-S41.
19. Habu D., Nishiguchi S., Nakatani S., Kawamura E., Lee C., Enomoto M., et al. Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol Res 2003, 25:312-318.
20. Kobayashi M., Ikeda K., Arase Y., Suzuki Y., Suzuki F., Akuta N., et al. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol 2008, 43:63-70.
21. Habu D., Nishiguchi S., Nakatani S., Lee C., Enomoto M., Tamori A., et al. Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. Hepatogastroenterology 2009, 56:1719-1723.
22. Shi J., Aisaki K., Ikawa Y., Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 1998, 153:515-525.
23. Patella S., Phillips D.J., Tchongue J., de Kretser D.M., Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 2006, 290:G137-G144.
24. Aram G., Potter J.J., Liu X., Wang L., Torbenson M.S., Mezey E. Deficiency of nicotinamide adenine dinucleotide phosphate, reduced form oxidase enhances hepatocellular injury but attenuates fibrosis after chronic carbon tetrachloride administration. Hepatology 2009, 49:911-919.
25. Karmen A., Wroblewski F., Ladue J.S. Transaminase activity in human blood. J Clin Invest 1955, 34:126-133.
26. Lubran M.M. The measurement of total serum proteins by the biuret method. Ann Clin Lab Sci 1978, 8:106-110.
27. Doumas B.T., Watson W.A., Biggs H.G. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 1971, 31:87-96.
28. Schafer T., Scheuer C., Roemer K., Menger M.D., Vollmar B. Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. FASEB J 2003, 17:660-667.
29. Blobel G., Potter V.R. Nuclei from rat liver: isolation method that combines purity with high yield. Science 1966, 154:1662-1665.
30. Miyasou T., Know A.H., Tsuji K., Qiu Z., Okumura T., Kamiyama Y. Edaravone prevents Fas-induced fulminant hepatic failure in mice by regulating mitochondrial Bcl-xL and Bax. Shock 2008, 30:212-216.
31. Marcellin P., Asselah T., Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36:S47-S56.
32. Suruki R., Hayashi K., Kusumoto K., Uto H., Ido A., Tsubouchi H., et al. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 2006, 119:192-195.
33. Bacon B.R. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002, 36:S179-S184.
34. Li G., Xie Q., Shi Y., Li D., Zhang M., Jiang S., et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006, 8:889-900.
35. George J., Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007, 14:790-803.
36. Chae H.J., Kim H.R., Xu C., Bailly-Maitre B., Krajewska M., Krajewski S., et al. BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol Cell 2004, 15:355-366.
37. Kotsafti A., Farinati F., Cardin R., Burra P., Bortolami M. Bax inhibitor-1 down-regulation in the progression of chronic liver diseases. BMC Gastroenterol 2010, 10:35.
38. Kuwahata M., Kubota H., Katsukawa M., Ito S., Ogawa A., Kobayashi Y., et al. Effect of branched-chain amino acid supplementation on the oxidized/reduced state of plasma albumin in rats with chronic liver disease. J Clin Biochem Nutr 2012, 50:67-71.
39. Freilinger A., Rosner M., Krupitza G., Nishino M., Lubec G., Korsmeyer S.J., et al. Tuberin activates the proapoptotic molecule BAD. Oncogene 2006, 25:6467-6479.
40. Wendel H.G., Silva R.L., Malina A., Mills J.R., Zhu H., Ueda T., et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007, 21:3232-3237.
41. Koreeda C., Seki T., Okazaki K., Ha-Kawa S.K., Sawada S. Effects of late evening snack including branched-chain amino acid on the function of hepatic parenchymal cells in patients with liver cirrhosis. Hepatol Res 2011, 41:417-422.